Deupirfenidone (LYT-100) in post-acute sequelae of SARS-CoV-2 with respiratory complications
Most patients with PASC and respiratory complications showed significant improvement over 91 days irrespective of treatment assignment. Deupirfenidone was well tolerated, with low rates of TEAEs, which supports further investigation in patients with idiopathic pulmonary fibrosis.
Authors
- Mark Harnett (ORCID: https://orcid.org/0000-0002-4652-3398)
- Tejaswini Kulkarni (ORCID: https://orcid.org/0000-0002-4251-4988)
- Camilla S. Graham (ORCID: https://orcid.org/0000-0003-0515-364X)
- Joel Santiaguel (ORCID: https://orcid.org/0009-0001-3951-0425)
- Toby M. Maher (ORCID: https://orcid.org/0000-0001-7192-9149)
- Michael C. Chen (ORCID: https://orcid.org/0000-0001-5178-4632)
- Julie Krop
- Raminder Aul (ORCID: https://orcid.org/0000-0002-7657-0099)
Institutions
- University of Southern California (US)
- Memorial Medical Center (US)
- St George’s University Hospitals NHS Foundation Trust (GB)
- Philippine General Hospital (PH)
- University of Alabama at Birmingham (US)
- PureTech (United States) (US)
- Biostatistical Consulting (United States) (US)
- Imperial College London (GB)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1183/23120541.01142-2024
- Primary Topic
- Pharmacological Receptor Mechanisms and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00